Advocacy at a Glance 5/2/21 Advocacy at a Glance 5/2/21 Key Take-Aways from Hill Day (Part One) Read More Analysis and Commentary 2/13/21 Analysis and Commentary 2/13/21 FDA-related Provision of House Reconciliation Bill Read More Advocacy at a Glance 2/13/21 Advocacy at a Glance 2/13/21 Under the House reconciliation bill, FDA would gain $500 million in no-year money to support its COVID-19 activities. The Alliance issued a statement of support for these funds. Read More Analysis and Commentary 1/8/21 Analysis and Commentary 1/8/21 Now We Know Who'll Be in Charge Read More Analysis and Commentary 10/16/20 Analysis and Commentary 10/16/20 Future Changes in Congressional Committees and the FDA Read More Analysis and Commentary 8/14/20 Analysis and Commentary 8/14/20 "Somehow the CR Will Pass", But When? Read More Advocacy at a Glance 8/1/20 Advocacy at a Glance 8/1/20 Advocacy at a Glance Read More Advocacy at a Glance 7/18/20 Advocacy at a Glance 7/18/20 Advocacy at a Glance Read More Advocacy at a Glance 6/5/20 Advocacy at a Glance 6/5/20 Advocacy at a Glance Read More Analysis and Commentary 9/20/19 Analysis and Commentary 9/20/19 More Questions and More Answers ... Once Again Read More Advocacy at a Glance 9/20/19 Advocacy at a Glance 9/20/19 Advocacy at a Glance Read More Analysis and Commentary 9/13/19 Analysis and Commentary 9/13/19 CR-Level Funding at Start of FY 20 Approaches Certainty Read More Analysis and Commentary 8/23/19 Analysis and Commentary 8/23/19 Sometimes Things Just Don't Go as Planned (or Hoped) Read More Analysis and Commentary 5/23/19 Analysis and Commentary 5/23/19 House Mark-up for FY 20 Very Pleasing Read More Advocacy at a Glance 5/23/19 Advocacy at a Glance 5/23/19 Advocacy at a Glance Read More Analysis and Commentary 11/2/18 Analysis and Commentary 11/2/18 Changes Are Inevitable. Some Predictable; Others Not Read More 9/7/18 9/7/18 Timing, Knowns, and Unknowns: FDA's FY 19 Appropriation Read More Analysis and Commentary 8/31/18 Analysis and Commentary 8/31/18 On the Physical Capabilities of a Lame Duck Read More Analysis and Commentary 5/24/18 Analysis and Commentary 5/24/18 FY 19 Funding: House and Senate Proposals Read More Advocacy at a Glance 5/24/18 Advocacy at a Glance 5/24/18 Advocacy at a Glance Read More Older Posts
Advocacy at a Glance 5/2/21 Advocacy at a Glance 5/2/21 Key Take-Aways from Hill Day (Part One) Read More
Analysis and Commentary 2/13/21 Analysis and Commentary 2/13/21 FDA-related Provision of House Reconciliation Bill Read More
Advocacy at a Glance 2/13/21 Advocacy at a Glance 2/13/21 Under the House reconciliation bill, FDA would gain $500 million in no-year money to support its COVID-19 activities. The Alliance issued a statement of support for these funds. Read More
Analysis and Commentary 1/8/21 Analysis and Commentary 1/8/21 Now We Know Who'll Be in Charge Read More
Analysis and Commentary 10/16/20 Analysis and Commentary 10/16/20 Future Changes in Congressional Committees and the FDA Read More
Analysis and Commentary 8/14/20 Analysis and Commentary 8/14/20 "Somehow the CR Will Pass", But When? Read More
Analysis and Commentary 9/20/19 Analysis and Commentary 9/20/19 More Questions and More Answers ... Once Again Read More
Analysis and Commentary 9/13/19 Analysis and Commentary 9/13/19 CR-Level Funding at Start of FY 20 Approaches Certainty Read More
Analysis and Commentary 8/23/19 Analysis and Commentary 8/23/19 Sometimes Things Just Don't Go as Planned (or Hoped) Read More
Analysis and Commentary 5/23/19 Analysis and Commentary 5/23/19 House Mark-up for FY 20 Very Pleasing Read More
Analysis and Commentary 11/2/18 Analysis and Commentary 11/2/18 Changes Are Inevitable. Some Predictable; Others Not Read More
Analysis and Commentary 8/31/18 Analysis and Commentary 8/31/18 On the Physical Capabilities of a Lame Duck Read More
Analysis and Commentary 5/24/18 Analysis and Commentary 5/24/18 FY 19 Funding: House and Senate Proposals Read More
